Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook

Sobi reported full-year 2025 revenue of approximately SEK 28.2 billion, about 15% growth at constant exchange rates, and an adjusted EBITA margin of roughly 40% of revenue, both ahead of its prior outlook. The upside was driven by stronger-than-expected Q4 sales of Doptelet, Gamifant and the haemophilia portfolio, versus an earlier expectation of low double-digit CER revenue growth and mid-to-high 30s EBITA margin. The company will publish the formal Q4 and full-year 2025 report on 5 February 2026, providing detailed financials and further context for investors.

Analysis

Market structure: Sobi (STO:SOBI) is the clear short-term winner — FY25 revenue ~SEK 28.2bn (+~15% CER) and adjusted EBITA ~40% (vs guidance mid/high-30s) implies stronger pricing power and faster uptake for Doptelet, Gamifant and haemophilia products. Competitors in niche rare-disease spaces face share loss where Sobi launches overlap; payers could push back, but near-term demand is robust, suggesting tighter supply-demand for these specialist drugs and higher realised ASPs. Cross-asset signal: positive domestic news should support SEK and reduce Sobi credit spreads; equity implied vol is likely to compress around the Feb 5 report, pressuring option sellers/buyers' timing choices.

Risk assessment: Tail risks include sudden reimbursement cuts in major markets (US Medicare/Medicaid policy, EU price reviews), regulatory label actions, or manufacturing single-point failures given product concentration; low-probability downside could wipe >30% of market cap. Immediate (days) sensitivity centers on the Feb 5 FY/Q4 report and Q1 revenue cadence; 1–6 month risks are payer coverage and inventory checks; 1–3 year risks hinge on pipeline execution and patent/competition. Hidden dependencies: partner/license terms, royalty expiries and US pricing reforms can materially shift margins; monitor gross-to-net trends and country mix within 30–90 days.

Trade implications: Event-driven long bias: establish a modest core long in SOBI ahead of Feb 5 to capture confirmation of momentum, then leverage with options if beat is confirmed. Pair trade idea: long SOBI vs short BioMarin (BMRN) to express execution/GM margin differential while hedging biotech beta; target 3–6 month horizon. Options: buy 1–3 month ATM calls (or call spreads) to limit theta loss — avoid straddles given expected IV compression post-release. Rotate 1–3% weight from broad-cap pharma ETF (e.g., XLV) into European specialty pharma long exposure if FY results sustain.

Contrarian angles: Consensus may underweight sustainability risk — the beat could be transitory if driven by channel stocking or one-off tender wins; conversely, markets may underprice takeover utility value if margins stay >35%. Historical parallel: successful rare-disease re-ratings (e.g., Shire pre-acquisition) show rapid multiple expansion but also M&A risk; unintended consequence: a strong beat can trigger payer scrutiny and tougher net pricing in 6–12 months. Monitor gross-to-net swing >3–5 p.p., country mix shifts, and any partner revenue cliffs within 60 days for signs the beat is not durable.

Key Decisions for Investors

• Establish a 2–4% long position in Sobi (STO:SOBI) ahead of the FY25/Q4 report on 5 Feb 2026; set a tactical target of +20–30% within 3 months and a hard stop-loss at −10% to limit event risk.
• Buy 1–3 month ATM call options on SOBI (or use a 3x/2x call spread to cap premium) sized at ~25% of the equity position to capture upside if the Feb 5 print accelerates uptake; avoid if implied vol >50%.
• Implement a dollar-neutral pair trade: long SOBI (2% portfolio) / short BioMarin (BMRN) (1–1.5% portfolio) to express superior execution/margin; rebalance or close after 3–6 months or if spread moves >15% adverse.
• Reduce broad-cap pharma ETF exposure (e.g., XLV) by ~1–2% and reallocate into European specialty pharma/rare-disease names led by SOBI if Sobi confirms sustained >35% adjusted EBITA margin in Q1 — verify by monitoring gross-to-net change >3 p.p. within 60–90 days.